Expertise in
4
conditions

Dr. Jaszianne Tolbert

Hematology | Oncology
Children's Mercy Kansas City
2401 Gillham Rd, 
Kansas City, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
4
conditions
Children's Mercy Kansas City
2401 Gillham Rd, 
Kansas City, MO 

Overview

Jaszianne Tolbert is a Hematologist and an Oncologist practicing medicine in Kansas City, Missouri.

Dr. Tolbert is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Reticulohistiocytoma, Histiocytosis, Langerhans Cell Histiocytosis, Hepatoblastoma, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 19 peer reviewed articles and participating in 17 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in KS

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Children's Mercy Kansas City
2401 Gillham Rd, Kansas City, MO 64108

Additional Areas of Focus

Dr. Tolbert has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Recruiting
Publish Date: June 05, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Inotuzumab, Leucovorin, 6-Mercaptopurine, Pegaspargase, Vincristine
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug
Study Drugs: Larotrectinib, Larotrectinib Sulfate
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Other, Drug
Study Drug: Erdafitinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug
Study Drug: Ulixertinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Other, Drug
Study Drug: Ensartinib
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Procedure, Drug
Study Drug: Trametinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: April 21, 2026
Intervention Type: Procedure, Drug
Study Drug: Samotolisib
Study Phase: Phase 2
View 9 Less Clinical Trials

19 Total Publications

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
Journal: The New England journal of medicine
Published: June 15, 2026
Similar Doctors
Expertise in
145
conditions
Dr. Jaswinder Singh
Hematology | Oncology
Expertise in
145
conditions
Dr. Jaswinder Singh
Hematology | Oncology
Referral may be required

Ascentist Physicians Group

4901 College Blvd, 
Leawood, KS 
 (11.4 miles away)
913-529-1801
Languages Spoken:
English
See accepted insurances

Jaswinder Singh is a Hematologist and an Oncologist practicing medicine in Leawood, Kansas. Dr. Singh is highly rated in 145 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Gallbladder Removal, and Bone Marrow Aspiration.

Expertise in
5
conditions
Dr. Alan Gamis
Hematology | Oncology
Expertise in
5
conditions
Dr. Alan Gamis
Hematology | Oncology
Referral may be required

Children's Mercy Kansas City

2401 Gillham Rd, 
Kansas City, MO 
 (0.1 miles away)
816-234-3265
Languages Spoken:
English
See accepted insurances

Alan Gamis is a Hematologist and an Oncologist practicing medicine in Kansas City, Missouri. Dr. Gamis is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Childhood Acute Myeloid Leukemia, Leukemia, Acute Megakaryoblastic Leukemia, Trisomy 3 Mosaicism, and Bone Marrow Transplant.

Expertise in
51
conditions
Dr. Abdulraheem Yacoub
Hematology
Expertise in
51
conditions
Dr. Abdulraheem Yacoub
Hematology
Referral may be required

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
 (5.1 miles away)
913-588-1227
Experience:
23+ years
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Abdulraheem Yacoub is a Hematologist practicing medicine in Fairway, Kansas. He has been practicing medicine for over 23 years. Dr. Yacoub is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Myelofibrosis, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Yacoub is board certified in American Board Of Internal Medicine, Hematology - 2012 and American Board Of Internal Medicine, Medical Oncology - 2011. Dr. Yacoub is currently accepting new patients.

Frequently Asked Questions about Dr. Jaszianne Tolbert

How do I make an appointment with Dr. Jaszianne Tolbert?

You can book an appointment with Dr. Jaszianne Tolbert by calling their office at 816-234-3000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jaszianne Tolbert a top-rated expert for Reticulohistiocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jaszianne Tolbert is classified as an Advanced expert for Reticulohistiocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jaszianne Tolbert specialize in?

While Dr. Jaszianne Tolbert is a Hematology, they have specific expertise in Reticulohistiocytoma, Histiocytosis, and Langerhans Cell Histiocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jaszianne Tolbert participate in research or clinical trials?

Yes. Dr. Jaszianne Tolbert has published 19 articles and abstracts on conditions like Reticulohistiocytoma. You can view a list of Dr. Jaszianne Tolbert's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tolbert's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile